CytoVeris’ Smart Cancer Imaging Solution
Proving what’s possible during surgery.
CytoVeris’ Smart Cancer Imaging Solution
Proving what’s possible during surgery.
OUR MISSION
To enhance the quality of intraoperative cancer detection through AI-powered imaging solutions, improving outcomes and accessibility for surgeons and patients.
Today, ensuring complete resection of breast cancer is challenging, often leading to poor outcomes and economic burden across the healthcare continuum.
Up to
of breast cancer resection have cancer left in the cavity
Estimated
in medical expenditures on breast cancer in the United States
Greater than
cost per year in secondary surgeries for breast cancer
Reduction of up to
of positive post-operative margins
Cost Savings of
to the U.S. healthcare system
* Based on feasibility studies that indicate a reduction of positive post-operative margins of up to 60%, which would result in a direct cost savings to the U.S. healthcare system of $600 million per year.
Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization
The Tumor Margin Assessment and Profiling System, TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.
All without the use of an imaging agent
Real-Time
Actionable Feedback to Surgeons
PRECISE
Tissue Margin Accuarcy
Workflow
Bringing the greatest effectiveness
Reduction
Of cost of breast cancer surgery
better outcomes
With fewer second surgeries
>> CLICK HERE TO LEARN MORE ABOUT ONCOSIGHT AI
OncoSIGHT AI™ is a proprietary, next generation tissue characterization algorithm that provides a safer, smarter and more reliable visualization of cancerous tissue.
We’re in the News
CytoVeris’ Platform Technology, TumorMAP™ powered by OncoSight AI™, relies on the intersection of natural characteristics of tissue and AI, and is in development to make a difference for patients across multiple disease areas.
Indication
Pre-clinical research
Feasibility Study
Pivotal Study
FDA Approval
